Resonance Health Joins Forces with Micron, Inc. for Strategic Entry into Japan's Healthcare Sector

28 March 2024 | Thursday | News

Strategic Alliance Set to Enhance Diagnostic Solutions in Japan, Expanding Access to Advanced Imaging Analysis in Clinical Trials and Medical Institutions
Image Source : Public Domain

Image Source : Public Domain

Resonance Health Ltd, listed on the Australian Securities Exchange (ASX) under the ticker RHT, has officially announced its strategic move into the Japanese market through a partnership with Micron, Inc., a Tokyo-based global leader in medical imaging solutions for clinical research organizations (CROs) and biopharmaceutical companies conducting clinical trials. This significant partnership is materialized through the signing of a Memorandum of Understanding & License Agreement, heralding a pivotal moment for Resonance Health as it brings its diagnostic imaging analysis products and services to Japan.

Micron, Inc., established as a molecular imaging contract research organization, provides an array of technical and clinical trial support services, including image analysis, PET tracer manufacturing, and site management. With a strong track record of assisting in the development and market launch of over 40 drugs across more than 250 clients, Micron's expertise lies in leveraging imaging services for the development of pharmaceuticals, diagnostics, biomarkers, and clinical development processes. Their notable INDICATE program aims to bridge the gap between international imaging specialist companies and the Japanese market, enhancing the adoption of new technologies, including AI-driven solutions.

This collaboration promises to significantly increase Resonance Health's exposure to the Japanese biopharmaceutical sector and medical institutions through Micron’s extensive network, thereby accelerating the company's growth within one of the world’s largest pharmaceutical markets. Japan's increasing liver cirrhosis cases, due to alcoholic-related diseases and non-alcoholic steatohepatitis (NASH), represent a critical area of need where Resonance's advanced diagnostic solutions can provide significant value.

Andrew Harrison, CEO of Resonance Health, expressed enthusiasm about the partnership, recognizing Micron's impressive service record and the lucrative opportunity it presents for entering the Japanese market with their innovative products and services.

This strategic move aligns with Resonance Health's broader strategy to expand its clinical trial and diagnostic services globally, leveraging Japan's substantial pharmaceutical market, which boasted sales revenues exceeding USD $100 billion in 2021. The partnership with Micron is set to fast-track Resonance Health’s growth and footprint in the Japanese healthcare and biopharmaceutical landscape, promising a new chapter of innovation and collaboration between these two esteemed entities.

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in